Specialty Pharmacy

The FDA today approved the expanded use of a breakthrough therapy for the treatment of a rare form of cancer that attacks the immune system.

System would provide more treatment options for patients along with evidence of drug safety and efficacy for regulators.

Kidneys transplanted from infant who died days after birth.

Pharmacists are getting closer to obtaining provider status, as federal legislation that would enable pharmacists to provide health care services to Medicare patients in underserved communities has been reintroduced in the US Senate and House of Representatives.

Benefits of tamoxifen varies among patients.

Researchers gain insight into the cause of fatigue in MS patients.

Vitamin D can stimulate the immune system to protect against a specific type of colorectal cancer.

Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses developing trends in the limited distribution of specialty medications.

Researchers discover how cancer resists BRAF+MEK inhibitors.

Eribulin evaluated for the first time as an early metastatic breast cancer treatment.

Chimeric antigen receptor may be able to treat a number of cancer types.

Pharmacists play an important role in ensuring optimal patient outcomes within accountable care organizations.

Popularity of new treatments lead to shrinking demand for Merck's Victrelis.

Pathway discovered that allows aggressive tumors to proliferate.

Protective effect less clear for cutaneous melanoma.

The Center for Pharmacy Practice Accreditation today announced the launch of a new accreditation program for specialty pharmacy practices. The application for accreditation and the newly approved specialty pharmacy accreditation standards are available at http://pharmacypracticeaccredit.org/.

Exclusive interviews with keynote speaker Lunden and program chairman Patrick I. Borgen, MD, of Maimonides Medical Center in Brooklyn, NY, outline cutting edge treatments for patients.

Stem cell transplantation associated with improvements in disability measures and quality of life.

High level of need cited among 9.5 million active and retired servicemen and their families.

Decrease attributed to less toxic therapies and risk reduction measures.

The FDA today approved Novartis' secukinumab (Cosentyx), an interleukin-17A antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Hospira has received 510(k) regulatory clearance from the FDA for its Plum 360 medication infusion system with Hospira MedNet safety software.

Process may reduce bowel obstructions and surgeries.

Although teixobactin is ineffective against most gram-negative organisms, its potent activity against gram-positive organisms, including vancomycin-resistant enterococci, may help delay the postantibiotic era by decades.

A new FDA-approved drug will provide a new treatment option for adult and pediatric patients undergoing continuous renal replacement therapy.

Raulo Frear, PharmD, general manager of OmedaRx, discusses methods to enhance management of drug utilization programs.

Study warns there is no testing to support a net clinical benefit.

Study finds lack of adherence to sun protection recommendations.